The T-cell engager (TCE) field has seen unprecedented growth, with eight approvals in the past two years—most recently tarlatamab—reinforcing its potential as a dominant force in immuno-oncology. Expanding applications in autoimmune diseases and a surge in business development, including Merck & Co.’s acquisition of Harpoon Therapeutics and GSK’s $550M agreement with Chimagen, highlight the industry’s commitment to advancing this modality.

The T-Cell Engager Therapeutics Summit remains the only event exclusively focused on translating TCEs and immune cell engagers from discovery to the clinic and regulatory approval. The 2025 program showcased innovations to improve efficacy and safety in solid tumors while exploring new opportunities in autoimmune indications.

Despite recent successes, challenges persist—identifying novel tumor targets, enhancing durability, reducing on-target, off-tumor toxicity, and optimizing dosing for first-in-human studies. The 2025 summit was your chance to gain the critical insights needed to overcome these hurdles and accelerate clinical success.

C-suite executives, biotech leaders, and pharma experts gathered in Boston to shape the future of T-cell engagers. With growing momentum and investment, it was the perfect time to stay ahead of the breakthroughs that drove the next wave of immune therapy innovation.